A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
暂无分享,去创建一个
Alain Viari | Thomas Bachelot | Michael R. Stratton | Daniel Birnbaum | Laurie Tonon | Anthony Ferrari | Jean-François Deleuze | Anne Vincent-Salomon | Gaëtan MacGrogan | Serena Nik-Zainal | Ivo Glynne Gut | Olivier Trédan | Sandrine Boyault | Sancha Martin | Anne-Sophie Sertier | Fabien Calvo | Pierre Saintigny | Marie-Christine Mathieu | Marta Gut | Odette Mariani | Frédéric Bibeau | Frédérique Penault-Llorca | Laurent Arnould | M. Stratton | D. Birnbaum | S. Nik-Zainal | Sancha Martin | G. Thomas | S. Boyault | O. Mariani | M. Gut | I. Gut | A. Vincent-Salomon | H. Blanché | G. MacGrogan | M. Mathieu | F. Penault-Llorca | H. Bonnefoi | G. Romieu | A. Viari | I. Pauporté | X. Pivot | I. Treilleux | J. Pierga | P. Saintigny | J. Deleuze | J. Jacquemier | O. Trédan | P. Fumoleau | C. Tarpin | S. Delaloge | T. Bachelot | F. Bibeau | E. Thomas | F. Calvo | L. Arnould | J. Ferrero | L. Tonon | A. Sertier | Eskeatnaf Mulugeta | Gilles Thomas | Hervé Bonnefoi | Jean-Marc Ferrero | Suzette Delaloge | Jean-Yves Pierga | Hélène Blanché | Jocelyne Jacquemier | Isabelle Treilleux | Pierre Fumoleau | Xavier Pivot | Janice Kielbassa | A. Ferrari | J. Kielbassa | Gilles Romieu | Carole Tarpin | Vincent Le Texier | Iris Pauporté | Emilie Thomas | Eskeatnaf Mulugeta | Cécile Mannina | Maria Rios | Catherine Bouteille | M. Rios | C. Bouteille | Vincent Le Texier | Cécile Mannina | G. Thomas
[1] F. Bertucci,et al. A refined molecular taxonomy of breast cancer , 2011, Oncogene.
[2] Kenny Q. Ye,et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.
[3] T. Meehan,et al. An atlas of active enhancers across human cell types and tissues , 2014, Nature.
[4] M. Ringnér,et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer , 2010, Breast Cancer Research.
[5] Simon Tavaré,et al. beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..
[6] B. Mcclintock,et al. The Stability of Broken Ends of Chromosomes in Zea Mays. , 1941, Genetics.
[7] C. Greenman,et al. Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process , 2015, Journal of Mathematical Biology.
[8] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[9] Nikolas von Bubnoff,et al. Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.
[10] A. Børresen-Dale,et al. Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.
[11] David G. Knowles,et al. Fast Computation and Applications of Genome Mappability , 2012, PloS one.
[12] P. Fasching,et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer , 2013, Breast Cancer Research.
[13] L. Pusztai,et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[15] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Baselga,et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. P. Benzécri,et al. Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire, addendum et erratum à [BIN. MULT.] , 1979 .
[18] Jörg Rahnenführer,et al. Robert Gentleman, Vincent Carey, Wolfgang Huber, Rafael Irizarry, Sandrine Dudoit (2005): Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2009 .
[19] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[20] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[21] Vineet Bafna,et al. An algorithmic approach for breakage-fusion-bridge detection in tumor genomes , 2013, Proceedings of the National Academy of Sciences.
[22] Carsten Denkert,et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Fox,et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.
[24] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[25] E. Perez,et al. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Hua Guo,et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. , 2010, The American journal of pathology.
[27] Hongjuan Zhao,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.
[28] N. Carter,et al. Estimation of rearrangement phylogeny for cancer genomes. , 2012, Genome research.
[29] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[30] Aleix Prat Aparicio. Comprehensive molecular portraits of human breast tumours , 2012 .
[31] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[32] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[34] I. Ial,et al. Nature Communications , 2010, Nature Cell Biology.
[35] Andrew Menzies,et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. , 2007, Genome research.
[36] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[37] Y. Benjamini,et al. Summarizing and correcting the GC content bias in high-throughput sequencing , 2012, Nucleic acids research.
[38] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[39] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[40] Johan Staaf,et al. Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios , 2008, BMC Bioinformatics.
[41] M. Espié,et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[42] M. Greenacre,et al. Multiple Correspondence Analysis and Related Methods , 2006 .
[43] Jan de Leeuw,et al. Interpreting multiple correspondence analysis as a multidimensional scaling method , 1992 .
[44] Simen Myhre,et al. The importance of gene-centring microarray data. , 2010, The Lancet. Oncology.
[45] Carlos Caldas,et al. TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance , 2014, Clinical Cancer Research.
[46] Rafael A. Irizarry,et al. Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .
[47] David Haussler,et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. , 2013, Cancer research.
[48] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[49] Zoltan Szallasi,et al. Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.
[50] Hisashi Tanaka,et al. A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications , 2012, Breast Cancer Research.
[51] D. Berry,et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Daniel Rios,et al. Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .
[53] Lovelace J. Luquette,et al. Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes , 2013, Cell.
[54] Vineet Bafna,et al. Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers , 2014, RECOMB.
[55] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[56] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[57] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[58] Daniel Birnbaum,et al. Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.
[59] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[60] C. Perou,et al. Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.
[61] Achim Rody,et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.
[62] M. Espié,et al. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[64] A. Laenkholm,et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[66] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[68] E. Barillot,et al. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays , 2009, Genome Biology.
[69] C. Greenman. Estimation of Rearrangement Phylogeny in Cancer , 2012 .
[70] P. Campbell,et al. OncoCis: annotation of cis-regulatory mutations in cancer , 2014, Genome Biology.
[71] R. Bernards,et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Jean Thioulouse,et al. ADE-4: a multivariate analysis and graphical display software , 1997, Stat. Comput..